Vaximm AG is a privately held Swiss-German biotechnology company focused on developing orally administered T-cell vaccination therapies using live, attenuated bacterial vectors to deliver tumor-associated antigens. The company’s lead candidate, VXM01, targets VEGFR-2 and has demonstrated clinical activity and safety across multiple cancer indications.
Leadership & Board
Current Number of Employees4
Current LinkedIn Followers1,009
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$30M
Total Amount Raised$30M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$30M
Latest Funding Amount$30M
Latest Funding RoundInvestment
Latest Funding RoundInvestment
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Vaximm AG had 4 employees as of September 28, 2026. The number of employees increased by 0 (0.00%) week-over-week.
4Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Vaximm AG had 1,009 followers as of September 28, 2026. The number of followers decreased by 2 (0.20%) week-over-week.
1,009Latest Followers Count
2(-0.20%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.